Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can growth hormone boost height in children with dwarfism?

NCT ID NCT05353192

Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing whether daily injections of recombinant human growth hormone can improve growth in children with achondroplasia, a genetic condition that causes short stature. The study will include children aged 2 to 10 who have not previously been treated with growth hormone. Over 52 weeks, researchers will measure changes in growth rate and height to see if the treatment is effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Recombinant human growth hormone
What this could lead to
If effective, this could offer a way to increase growth and height in children with achondroplasia, potentially improving their quality of life.
What could go wrong
This is a small, single-arm study without a placebo group, so results may be less reliable. Growth hormone may not significantly improve height and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

39 people

The number who actually took part.

Started

Aug 2022

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 10 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 2-10 years old; * In Tanner I stage; * ACH, documented and confirmed by genetic testing; * Short stature; * Ambulatory and able to stand or walk without assistance; * Parent(s) or guardian(s) consent； * Had never been treated with growth hormone Exclusion criteria: * Short stature condition other than ACH; * Evidence of growth plate closure (proximal tibia, distal femur); * Had a fracture of the long bones within 6 months prior to screening; * Planned or expected bone-related surgery; * Chronic diseases condition that affect bone metabolism and weight; * Severe intracranial hypertension

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Achondroplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

achondroplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Achondroplasia

Contacts and locations

Locations

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, 201102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.